Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
- Conditions
- Myocardial Infarction
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1899
- Registration Number
- NCT00623623
- Locations
- 🇮🇹
1123.28.39001A Boehringer Ingelheim Investigational Site, Monza, Italy
🇫🇷1123.28.3329A Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France
🇫🇷1123.28.3329C Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France
Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2010-12-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 8329
- Registration Number
- NCT00622648
- Locations
- 🇹🇳
Sanofi-Aventis Administrative Office, Megrine, Tunisia
Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2011-03-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT00622115
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
- Conditions
- ObesityVenous ThrombosisAnticoagulants
- Interventions
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 28
- Registration Number
- NCT00585182
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8101
- Registration Number
- NCT00571649
- Locations
- 🇦🇷
Sanatorio Mitre, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
🇨🇦CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
🇨🇦Hotel Dieu-Grace Hospital, Windsor, Ontario, Canada
Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
- Conditions
- Venous Thrombosis
- Interventions
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Lehigh Valley Hospital
- Target Recruit Count
- 1
- Registration Number
- NCT00521885
- Locations
- 🇺🇸
Lehigh Valley Hospital Muhlenberg, Bethlehem, Pennsylvania, United States
Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Canadian Heart Research Centre
- Target Recruit Count
- 11
- Registration Number
- NCT00518245
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 27
- Registration Number
- NCT00493896
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
- Conditions
- Venous ThrombosisPulmonary Embolism
- Interventions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6758
- Registration Number
- NCT00457002
- Locations
- 🇺🇸
Pulmonary & Critical Care Of Atlanta, Atlanta, Georgia, United States
🇺🇸Atlanta Institute For Medical Research, Inc, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
- Conditions
- Pulmonary EmbolismDeep Vein Thrombosis
- Interventions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3221
- Registration Number
- NCT00452530
- Locations
- 🇬🇧
Local Institution, Epsom, Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.